Alpha-lipoic acid (ALA, also known as thioctic acid) is a naturally occurring dithiol compound that functions as a cofactor for mitochondrial enzyme complexes involved in energy metabolism. Unlike most antioxidants, which are either fat-soluble (vitamin E) or water-soluble (vitamin C), ALA is both — it operates in aqueous and lipid environments, and it can regenerate other antioxidants including vitamin C, vitamin E, and glutathione. ALA is sometimes described as the "universal antioxidant."
Small amounts of ALA are synthesised endogenously and found in food sources such as spinach, broccoli, tomatoes, organ meats, and yeast. However, supplemental doses are far higher than dietary intake — and the supplement form has been prescribed as a pharmaceutical in Germany for diabetic neuropathy for over 30 years. This pharmaceutical history in Europe means ALA has a more robust clinical evidence base than most supplements.
Supplements sold in Irish health shops are typically either racemic ALA (a 50:50 mix of R-ALA and S-ALA isomers) or R-ALA specifically. The R form is the biologically active isomer occurring naturally in the body.
The ALA in Diabetic Neuropathy (ALADIN) series of trials, conducted by Ziegler and colleagues in Germany throughout the 1990s, represents the strongest clinical evidence for ALA in peripheral neuropathy. These were multicentre, randomised, double-blind, placebo-controlled trials funded with government and academic support — a rigorous design rarely seen in supplement research.
ALADIN I (1995): 328 patients with type 2 diabetes and symptomatic peripheral neuropathy received IV ALA (100 mg, 600 mg, or 1,200 mg) or placebo daily for three weeks. The 600 mg IV group showed a statistically significant reduction in the Total Symptom Score (TSS) — measuring burning, stabbing, tingling, and numbness — compared to placebo (p<0.002). The 100 mg and 1,200 mg groups showed smaller, less significant improvements, suggesting 600 mg was the optimal IV dose.
ALADIN III (1999): Investigated sequential IV then oral ALA (600 mg/day) vs placebo. Results showed continued symptom improvement in the ALA group, supporting the transition from IV to oral maintenance therapy.
SYDNEY 2 (2006): The most clinically practical trial — 181 patients randomised to oral ALA 600 mg, 1,200 mg, or 1,800 mg/day or placebo for five weeks. All three ALA doses significantly reduced TSS scores compared to placebo. The 600 mg/day dose had the best tolerability profile without sacrificing efficacy — the recommended clinical dose that emerged from the ALADIN series.
A meta-analysis by Ziegler et al. (2004) across four large RCTs confirmed that IV ALA at 600 mg/day significantly improved neuropathic symptoms in diabetic patients, with a consistent and clinically meaningful effect. This meta-analysis was published in Diabetic Medicine and is the most authoritative summary of the evidence base.
Most of the definitive ALADIN trials used IV administration. The oral evidence is less extensive and shows smaller effect sizes — partly because oral bioavailability of standard racemic ALA is variable (20–40%) due to food interaction and first-pass metabolism. R-ALA has better bioavailability than the racemic form and is increasingly used in clinical practice. Some practitioners advocate stabilised R-ALA (sodium R-ALA or R-ALA with cyclodextrin) for improved absorption.
| Claim | Evidence Level | Source |
|---|---|---|
| Reduces diabetic neuropathy symptoms (IV) | Strong | ALADIN I, III; Ziegler meta-analysis 2004 (Diabetic Medicine) |
| Reduces neuropathy symptoms (oral 600 mg/day) | Moderate | SYDNEY 2 trial 2006 (n=181, double-blind) |
| Regenerates glutathione and vitamin E | Strong (biochemical) | Well-established metabolic function |
| Improves insulin sensitivity | Moderate | Jacob et al. 1999; multiple small RCTs |
| Treats non-diabetic neuropathy | Limited | Small trials in HIV neuropathy, chemotherapy neuropathy |
Standard supplement-grade ALA is racemic — equal parts R and S isomers. Only the R isomer occurs naturally in the body and is biologically active. The S isomer is not toxic but may competitively inhibit R-ALA uptake at high doses. R-ALA supplements are more expensive but theoretically deliver double the active compound at the same stated dose. For general antioxidant use, racemic ALA is adequate. For therapeutic neuropathy applications, R-ALA or high-dose racemic ALA are preferred by many practitioners.
The most evidence-supported oral dose for neuropathy is 600 mg/day, taken on an empty stomach (food significantly reduces absorption — ALA should be taken 30 minutes before meals). For antioxidant and metabolic support, 300–600 mg/day is typical. R-ALA doses are typically 150–300 mg (equivalent activity to 300–600 mg racemic).
ALA has a good safety profile at standard doses. The most commonly reported side effects are GI (nausea, stomach cramps), particularly on an empty stomach. At very high doses (>1,200 mg/day), headache and skin rash have been reported.
Blood sugar lowering: ALA can reduce blood glucose, likely through improved insulin sensitivity. In people on insulin or oral antidiabetic agents, this may cause hypoglycaemia. Monitor blood sugar carefully when starting ALA if on diabetes medication.
ALA can chelate metals, including iron, copper, and zinc. High-dose long-term supplementation may reduce mineral absorption — take separately from mineral supplements by at least two hours.
ALA may interact with thyroid medications — it can decrease T4 to T3 conversion in some individuals. Monitor thyroid function if on levothyroxine and starting ALA supplementation.
Alpha-lipoic acid has the strongest clinical evidence of perhaps any supplement for a specific condition — diabetic peripheral neuropathy. The ALADIN trial series is rigorous by supplement standards, and the German pharmaceutical designation for ALA in neuropathy reflects this evidence quality. Oral ALA at 600 mg/day is a legitimate evidence-based option for people with diabetic neuropathy, ideally in conjunction with blood sugar management. The blood sugar-lowering interaction requires monitoring in anyone on antidiabetic medication. For general antioxidant purposes, ALA is well-supported biochemically and safe at lower doses.